Compare · PDEX vs WST
PDEX vs WST
Side-by-side comparison of Pro-Dex Inc. (PDEX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PDEX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.23B, about 117.0x PDEX ($198.6M).
- Over the past year, PDEX is up 54.3% and WST is up 48.0% - PDEX leads by 6.3 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 1 for PDEX).
- WST has more recent analyst coverage (17 ratings vs 0 for PDEX).
- Company
- Pro-Dex Inc.
- West Pharmaceutical Services Inc.
- Price
- $61.25-1.84%
- $328.50-0.60%
- Market cap
- $198.6M
- $23.23B
- 1M return
- +1.65%
- +8.67%
- 1Y return
- +54.30%
- +48.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 17
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest PDEX
- Chief Executive Officer Van Kirk Richard Lee Jr sold $626,248 worth of shares (10,000 units at $62.62) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 89,707 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month Results
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)